MetLife (MET) director receives 721-share stock grant as deferred board fees

Rhea-AI Filing Summary

Mumenthaler Christian Stephane reported acquisition or exercise transactions in this Form 4 filing.

METLIFE INC director Christian Stephane Mumenthaler received an equity grant of MetLife common stock as part of his board compensation. On this Form 4, he was awarded 721 shares of common stock at $71.17 per share, increasing his directly reported holdings to 2,846 shares. The footnote explains that MetLife pays a portion of non-management director retainer fees in common stock and that he elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, so the compensation is taken in stock units rather than immediate cash.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mumenthaler Christian Stephane

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	721	$71.17	$51K

Holdings After Transaction: Common Stock — 2,846 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 721 shares Grant price: $71.17 per share Shares owned after grant: 2,846 shares

3 metrics

Shares granted 721 shares Non-management director stock compensation award

Grant price $71.17 per share Recorded price for the 721-share award

Shares owned after grant 2,846 shares Director’s directly reported holdings following the transaction

Key Terms

non-management director retainer fees, Deferred Compensation Plan for Non-Management Directors, Grant, award, or other acquisition

3 terms

non-management director retainer fees financial

"non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock"

Deferred Compensation Plan for Non-Management Directors financial

"elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors"

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mumenthaler Christian Stephane

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A(1)		721	A	$71.17	2,846	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MET (MetLife) report for Christian Stephane Mumenthaler?

MetLife reported that director Christian Stephane Mumenthaler received a grant of 721 shares of common stock. The shares represent non-management director compensation and increased his directly reported holdings to 2,846 shares following the transaction.

Was the MetLife (MET) Form 4 transaction a market purchase or a compensation award?

The Form 4 shows a compensation award, not an open-market trade. Code "A" indicates a grant or award acquisition, reflecting non-management director retainer fees paid partly in MetLife common stock rather than a discretionary stock purchase.

How many MetLife (MET) shares does Christian Stephane Mumenthaler hold after this Form 4?

After the reported grant, Christian Stephane Mumenthaler directly holds 2,846 shares of MetLife common stock. This total includes the newly awarded 721 shares that were credited as part of his non-management director compensation arrangements.

What price per share was used for the MetLife (MET) director stock grant?

The director stock grant was recorded at $71.17 per share. This price is used in the Form 4 disclosure to value the 721-share equity award that forms part of Christian Stephane Mumenthaler’s non-management director retainer compensation.

Did the MetLife (MET) director defer the stock received in this transaction?

Yes. The footnote states that the director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning the stock-based retainer is deferred rather than immediately delivered as shares.

How are MetLife (MET) non-management directors compensated according to this filing?

The filing explains that MetLife’s non-management director compensation arrangements pay a portion of retainer fees in MetLife common stock. Directors can elect to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.